LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase

Abstract

LY3045697 is a potent and highly selective aldosterone synthase inhibitor with selectivity for CYP11B2, offering a substantial potential advantage over previous aldosterone synthase inhibitors evaluated in the clinic.